2025
Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study
Donnez J, Petraglia F, Taylor H, Becker C, Becker S, Herrera F, Bestel E, Hori S, Dolmans M. Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study. Fertility And Sterility 2025 PMID: 40543832, DOI: 10.1016/j.fertnstert.2025.06.016.Peer-Reviewed Original ResearchHormonal add-back therapyAdd-back therapyHeavy menstrual bleedingMenstrual blood lossSymptomatic uterine fibroidsCessation of therapyMenstrual bleedingBone mineral densityUterine fibroidsBlood lossWithdrawal studyMineral densityPlacebo-controlled phase 3 trialTreatment of symptomatic uterine fibroidsDecreased menstrual blood lossReducing menstrual blood lossRisk of bone lossReducing heavy menstrual bleedingExtension studySignificantly higher proportion of womenMonths of therapyFibroid-associated symptomsPhase 3 trialAlkaline haematin methodBenefits of treatmentMenstrual product use patterns in a large digital cohort in the United States: Variations by sociodemographic, health, and menstrual characteristics
Wang Z, Peebles E, Baird D, Jukic A, Wilcox A, Curry C, Fischer-Colbrie T, Onnela J, Williams M, Hauser R, Coull B, Mahalingaiah S. Menstrual product use patterns in a large digital cohort in the United States: Variations by sociodemographic, health, and menstrual characteristics. American Journal Of Obstetrics And Gynecology 2025 PMID: 40073916, DOI: 10.1016/j.ajog.2025.03.002.Peer-Reviewed Original ResearchSocioeconomic statusSuper absorbent tamponsMenstrual characteristicsConfidence intervalsUS cohortNon-Hispanic white participantsApple Women's Health StudyWomen's Health StudyNon-Hispanic blacksTampon usersBleeding daysGynecologic conditionsMenstrual productsUnited StatesHealth StudyUS adultsHispanic individualsChi-square testWhite participantsProduct useDemographic factorsMenstrual bleedingHealthTampon useParticipants
2024
Cost-Effectiveness of Oral Versus Intravenous First-Line Treatment of Severe Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding
Wang D, Wang D, Glaeser-Khan S, Moshashaian Asl R, Chetlapalli K, Ito S, Cuker A, Goshua G. Cost-Effectiveness of Oral Versus Intravenous First-Line Treatment of Severe Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding. Blood 2024, 144: 281-281. DOI: 10.1182/blood-2024-198803.Peer-Reviewed Original ResearchSevere iron deficiency anemiaHeavy menstrual bleedingIron deficiency anemiaOral ferrous sulfateIncremental cost-effectiveness ratioIV iron sucroseIV iron dextranFirst-line treatmentFirst-lineIron sucroseQuality-adjusted life expectancyOral ironSecond-lineDeterministic sensitivity analysisProbabilistic sensitivity analysesIron dextranMenstrual bleedingDeficiency anemiaIron deficiencyUS health system perspectiveTreated with oral ironIV iron supplementationIV iron treatmentOral iron therapyDevelopment of iron deficiencyDoes the shape of the copper intrauterine device play a role in expulsion? Results from the ongoing European Active Surveillance Study on LCS12
Boehnke T, Bauerfeind A, Eggebrecht L, Cellier C, Lange J, Heinemann K, Madden T. Does the shape of the copper intrauterine device play a role in expulsion? Results from the ongoing European Active Surveillance Study on LCS12. Contraception 2024, 140: 110444. PMID: 38552821, DOI: 10.1016/j.contraception.2024.110444.Peer-Reviewed Original ResearchConceptsCopper intrauterine deviceEuropean Active Surveillance StudyIntrauterine deviceCopper IUD usersActive surveillance studyNova-TFrameless intrauterine deviceRisk of expulsionIUD usersIntrauterine ballHazard ratioSurveillance studyHeavy menstrual bleedingCox regression analysisIncidence of expulsionHigher risk of expulsionMenstrual bleedingCumulative incidenceCounseling patientsClinical importanceLow riskHigh riskSecondary analysisClinician experienceCliniciansUterine fibroid–related infertility: mechanisms and management
Donnez J, Taylor H, Marcellin L, Dolmans M. Uterine fibroid–related infertility: mechanisms and management. Fertility And Sterility 2024, 122: 31-39. PMID: 38453041, DOI: 10.1016/j.fertnstert.2024.02.049.Peer-Reviewed Original ResearchUterine artery embolizationUterine fibroidsAssociation of fibroidsAdd-back therapyHeavy menstrual bleedingBaseline to weekOral GnRH antagonistPresence of fibroidsNon-surgical approachFocused ultrasoundFibroid volumeMyoma volumeArtery embolizationMenstrual bleedingCurrent management strategiesGnRH antagonistEchographic guidanceSurgical interventionFibroidsInfertilityMedical treatmentUterineWomenOptimal dosageSource of controversy
2023
Standardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome set
Cooper N, Rivas C, Munro M, Critchley H, Clark T, Matteson K, Papadantonaki R, Yorke S, Tan A, Rodriguez M, Bongers M, Al‐Hendy A, Bahamondes L, Connolly A, Farquhar C, Valbrun T, Hickey M, Taylor H, Toub D, Vannuccini S, Iliodromiti S, Khan K. Standardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome set. BJOG An International Journal Of Obstetrics & Gynaecology 2023, 130: 1337-1345. PMID: 37055716, DOI: 10.1111/1471-0528.17473.Peer-Reviewed Original ResearchConceptsHeavy menstrual bleedingCore outcomeFinal COSMenstrual bleedingClinical trialsConsensus meetingSystematic reviewSeverity of dysmenorrhoeaNumber of patientsPotential core outcomesInternational Consensus MeetingQuality of lifeDelphi surveyTwo-round Delphi surveyAdverse eventsBlood lossHemoglobin levelsFuture trialsGynecology DepartmentCOMET InitiativePatient satisfactionClinical guidelinesResource settingsOnline international surveyFurther treatment
2022
Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States
Corrales-Medina F, Raffini L, Recht M, Santos J, Thornburg C, Davila J, Investigators A. Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States. Research And Practice In Thrombosis And Haemostasis 2022, 7: 100001. PMID: 36970740, PMCID: PMC10031368, DOI: 10.1016/j.rpth.2022.100001.Peer-Reviewed Original ResearchPrevention of venous thromboembolismVenous thromboembolismOral anticoagulantsPediatric hematologistsClinically relevant nonmajor bleeding eventsTreatment of acute venous thromboembolismSecondary prevention of venous thromboembolismUS Food and Drug Administration approvalFood and Drug Administration approvalRecurrent thrombosis rateDirect oral anticoagulantsAcute venous thromboembolismNonmajor bleeding eventsPediatric venous thromboembolismDrug Administration approvalFemales aged >Prescribed DOACsDOAC useBleeding complicationsBleeding eventsMenstrual bleedingAnticoagulation regimenDOACsAdministration approvalOff-labelLinzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials
Donnez J, Taylor HS, Stewart EA, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland JP, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. The Lancet 2022, 400: 896-907. PMID: 36116480, DOI: 10.1016/s0140-6736(22)01475-1.Peer-Reviewed Original ResearchConceptsHeavy menstrual bleedingPhase 3 trialSymptomatic uterine fibroidsMenstrual bleedingUterine fibroidsTherapy groupPlacebo groupOral gonadotropin-releasing hormone receptor antagonistResponse rateGonadotropin-releasing hormone receptor antagonistCommon adverse eventsFull analysis setHormone receptor antagonistDose of treatmentMasked treatmentPrimary endpointStudy drugAdverse eventsEligible womenHot flushesChronic treatmentReceptor antagonistGonadal steroidsLinzagolixAnalysis setA 43-Year-Old Woman With Fatigue, Pancytopenia, and Mediastinal Adenopathy
Zeba F, Marotti J, Feller-Kopman D. A 43-Year-Old Woman With Fatigue, Pancytopenia, and Mediastinal Adenopathy. CHEST Journal 2022, 161: e293-e297. PMID: 35526899, DOI: 10.1016/j.chest.2021.12.653.Peer-Reviewed Original ResearchConceptsFamily history of malignancyHistory of malignancyHeavy menstrual bleedingAdmitted with fatigueSignificant medical historyShortness of breathFamily historySmoking habitsJoint painNeck swellingMediastinal adenopathyMenstrual bleedingEnvironmental exposuresNight sweatsMedical historyWeight lossWomenCurrent presentFatigueSmokingAdenopathyPancytopeniaMediastinitisMalignancyMedicationPost-treatment Efficacy and Safety Follow-up in Women with Uterine Fibroids Treated for 52 Weeks With Linzagolix [A108]
Taylor H, Donnez J, Bestel E, Humberstone A, Garner E. Post-treatment Efficacy and Safety Follow-up in Women with Uterine Fibroids Treated for 52 Weeks With Linzagolix [A108]. Obstetrics And Gynecology 2022, 139: 31s-32s. DOI: 10.1097/01.aog.0000826752.16466.97.Peer-Reviewed Original ResearchBone mineral densityUterine fibroidsWeek 64Placebo-controlled phase 3 trialLumbar spine bone mineral densityTreatment of UFsSpine bone mineral densityHeavy menstrual bleedingPhase 3 trialWeeks of dosingHealth-related qualityCompletion of treatmentTreatment of womenEfficacy endpointPost-treatment efficacyTreatment discontinuationUterine bleedingWeek 52Key efficacyWeek 76Menstrual bleedingFibroid volumeMedian timeFollow-upMineral density
2021
O-135 Long term secondary efficacy of linzagolix for heavy menstrual bleeding (HMB) due to uterine fibroids (UF): 52-week results from two placebo-controlled, randomized, phase 3 trials
Taylor H, Donnez J, Petraglia F, Danielsson K, Renner S, Bestel E, Gotteland J, Humberstone A, Garner E. O-135 Long term secondary efficacy of linzagolix for heavy menstrual bleeding (HMB) due to uterine fibroids (UF): 52-week results from two placebo-controlled, randomized, phase 3 trials. Human Reproduction 2021, 36: deab126.060. DOI: 10.1093/humrep/deab126.060.Peer-Reviewed Original ResearchHeavy menstrual bleedingQuality of lifePhase 3 trialWeeks of treatmentUterine fibroidsPain scoresSecondary endpointsMenstrual bleedingMean agePlacebo-controlled phase 3 trialPotential long-term treatmentOral GnRH antagonistSecondary efficacy assessmentsTrial subjectsTRIAL REGISTRATION NUMBERDifferent treatment regimensLong-term treatmentPARTICIPANTS/MATERIALSROLE OF CHANCEMaintenance of effectsSymptom recurrenceSecondary efficacySymptomatic improvementWeek 24Anemic patients
2020
Hemostatic Therapies for Heavy Menstrual Bleeding
Ahuja S, Recht M, Konkle B. Hemostatic Therapies for Heavy Menstrual Bleeding. 2020, 119-127. DOI: 10.1007/978-3-030-48446-0_11.Peer-Reviewed Original ResearchHeavy menstrual bleedingMenstrual blood lossNonsteroidal anti-inflammatory drugsVon Willebrand diseaseHemostatic therapyMenstrual bleedingPlatelet disordersAnti-fibrinolyticsBleeding disorder diagnosisCoagulation factor replacementHormonal contraceptive therapyInherited platelet disordersFresh frozen plasmaDiagnosis of hemophilia AContext of painHemophilia A carriersFirst-line approach to treatmentAnti-inflammatory drugsMedical management strategiesContraceptive therapyApproach to treatmentHormone therapyPlatelet transfusionsBlood lossFactor replacementA Cross-Sectional Study of Women and Girls with Congenital Bleeding Disorders: The American Thrombosis and Hemostasis Network Cohort
Haley K, Sidonio R, Abraham S, Cheng D, Recht M, Kulkarni R. A Cross-Sectional Study of Women and Girls with Congenital Bleeding Disorders: The American Thrombosis and Hemostasis Network Cohort. Journal Of Women's Health 2020, 29: 670-676. PMID: 31905045, DOI: 10.1089/jwh.2019.7930.Peer-Reviewed Original ResearchConceptsVon Willebrand diseaseCongenital bleeding disordersBleeding disordersBleeding symptomsBleeding disorder diagnosisReproductive tract bleedingHeavy menstrual bleedingRetrospective cohort studyHemophilia treatment centersStudy of womenCross-sectional studyMenstrual bleedingTract bleedingATHNdatasetCohort studyWillebrand diseaseBleedingDemographic dataAmerican ThrombosisEpidemiological dataImprove diagnosisMethods:</i></b>CohortDiagnosisDescriptive statistics
2019
Implementation of the uterine fibroids Option Grid patient decision aids across five organizational settings: a randomized stepped-wedge study protocol
Scalia P, Durand M, Forcino R, Schubbe D, Barr P, O’Brien N, O’Malley A, Foster T, Politi M, Laughlin-Tommaso S, Banks E, Madden T, Anchan R, Aarts J, Velentgas P, Balls-Berry J, Bacon C, Adams-Foster M, Mulligan C, Venable S, Cochran N, Elwyn G. Implementation of the uterine fibroids Option Grid patient decision aids across five organizational settings: a randomized stepped-wedge study protocol. Implementation Science 2019, 14: 88. PMID: 31477140, PMCID: PMC6721118, DOI: 10.1186/s13012-019-0933-z.Peer-Reviewed Original ResearchConceptsPatient decision aidOption GridUterine fibroidsNormalization Process TheoryOutcome measuresMulti-component implementation strategyHeavy menstrual bleedingPrimary outcome measureMultiple treatment optionsYears of ageQuantitative outcome measuresBackgroundUterine fibroidsEligible patientsPelvic painPostmenopausal patientsPregnancy complicationsRecurrent symptomsDifferent time pointsMenstrual bleedingRoutine careTreatment optionsFemale sexStudy protocolClinician characteristicsTreatment decisions
2018
Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding
Rocheleau A, Khader A, Ngo A, Boehnlein C, McDavitt C, Lattimore S, Recht M, McCarty O, Haley K. Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding. Pediatric Research 2018, 83: 693-701. PMID: 29166373, PMCID: PMC5902421, DOI: 10.1038/pr.2017.298.Peer-Reviewed Original ResearchConceptsHeavy menstrual bleedingVon Willebrand factorBleeding disordersPlatelet functionCollagen-related peptideAdolescent womenMenstrual bleedingGPIIbIIIa activationAdenosine diphosphateAberrant platelet functionResponse to ADPResponse to multiple agonistsTests of platelet functionPopulation of adolescent womenResponse to calcium ionophorePlatelet function assaysQualitative platelet disordersWhole blood assayPlatelet disordersCalcium ionophoreTRAP-6BD diagnosisMultiple agonistsPlatelet activationPlatelet adhesion
2017
Stress and Implantation Failure
Deaton J, Patel B, Johnston-MacAnanny E, Yu J, Whirledge S, Wilson A, David Wininger J, Shu Y, Taylor R, Berga S. Stress and Implantation Failure. 2017, 103-124. DOI: 10.1007/978-3-319-71967-2_7.Peer-Reviewed Original ResearchImplantation failureHCG productionSecretion of estradiolHPO axisMenstrual bleedingOvarian axisEndometrial developmentMetabolic factorsElevated glucocorticoidsEndometriumInappropriate exposureEndocrine signalsLaboratory stressorPutative mechanismsQuantitative exposureImplantationFemale reproductionEstradiolOvulationHealthy blastocystAlterationsFailureExposureBleedingObesityCurrent and Emerging Medical Treatments for Uterine Fibroids
Chwalisz K, Taylor H. Current and Emerging Medical Treatments for Uterine Fibroids. Seminars In Reproductive Medicine 2017, 35: 510-522. PMID: 29100239, DOI: 10.1055/s-0037-1606302.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyCost of IllnessDrug ApprovalDrugs, InvestigationalEvidence-Based MedicineFemaleGonadotropin-Releasing HormoneHormone AntagonistsHumansLeiomyomaLeiomyomatosisMenorrhagiaQuality of LifeReceptors, ProgesteroneUnited StatesUnited States Food and Drug AdministrationUterine NeoplasmsConceptsUterine fibroidsMedical therapyMedical treatmentOral gonadotropin-releasing hormone antagonistLong-term medical therapyGonadotropin-releasing hormone antagonistCommon uterine neoplasmPressure-related symptomsHeavy menstrual bleedingProgesterone receptor modulatorsRandomized clinical trialsSymptomatic uterine fibroidsUnited States FoodMenstrual bleedingUterine neoplasmsSymptom managementSurgical interventionHormone antagonistClinical trialsReceptor modulatorsMedical optionsEffective treatmentClinical developmentFibroidsDrug AdministrationHormonal regulation of the endometrium and the effects of hormonal therapies
Ersoy G, Modi M, Alderman M, Taylor H. Hormonal regulation of the endometrium and the effects of hormonal therapies. 2017, 161-176. DOI: 10.1201/9781315151472-11.ChaptersSelective progesterone receptor modulatorsSelective estrogen receptor modulatorsMenopausal hormone therapyIntrauterine deviceOral contraceptivesMedroxyprogesterone acetateMenstrual cycleReceptor modulatorsGonadotropin-releasing hormone agonistProgesterone receptor modulatorsEstrogen receptor modulatorsHuman menstrual cycleHormonal regulationPractice of obstetricsHormonal therapyHormone therapyMenstrual bleedingEndometrial receptivityHormone agonistTestosterone signalingHormonal treatmentSecretory phaseEmbryo implantationEndometriumProliferative phase
2016
Identification of Qualitative Platelet Disorders in Adolescent Women with Heavy Menstrual Bleeding
Haley K, Lattimore S, McDavitt C, Khader A, Boehnlein C, Baker-Groberg S, Ngo A, McCarty O, Recht M. Identification of Qualitative Platelet Disorders in Adolescent Women with Heavy Menstrual Bleeding. Blood 2016, 128: 4922. DOI: 10.1182/blood.v128.22.4922.4922.Peer-Reviewed Original ResearchHeavy menstrual bleedingBleeding disorder diagnosisQualitative platelet disordersEntity's Board of DirectorsPlatelet function assaysPictorial Bleeding Assessment ChartPlatelet disordersPlatelet functionAdolescent womenBleeding phenotypeMenstrual bleedingPlatelet aggregationQuality of lifeBleeding disordersCSL BehringEvaluation of heavy menstrual bleedingAbnormal platelet function testsISTH bleeding assessment toolEtiology of heavy menstrual bleedingFunctional assaysMedian PBAC scoreResponse to agonist stimulationPlatelet function abnormalitiesBleeding assessment toolAssessment of platelet activationAssociation of baseline bleeding pattern on amenorrhea with levonorgestrel intrauterine system use
Mejia M, McNicholas C, Madden T, Peipert J. Association of baseline bleeding pattern on amenorrhea with levonorgestrel intrauterine system use. Contraception 2016, 94: 556-560. PMID: 27364099, PMCID: PMC5077249, DOI: 10.1016/j.contraception.2016.06.013.Peer-Reviewed Original ResearchConceptsLNG-IUS useEffect of baselineBleeding patternsMonths postinsertionLevonorgestrel intrauterine system useLikelihood of amenorrheaRates of amenorrheaHeavy menstrual bleedingHeavy menstrual flowMonths of enrollmentMultivariable logistic regressionIntrauterine system useIntrauterine system usersLNG-IUS usersContraceptive CHOICE ProjectMonths of useMenstrual bleedingModerate bleedingMultivariable analysisHeavy bleedingLNG-IUSMenstrual flowContraceptive counselingUnintended pregnancyBaseline bleeding
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply